Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam

Keyphrases

• Budesonide 100%
• Remission 100%
• Clinical Remission 100%
• Ulcerative Colitis Patient 100%
• Ulcerative Colitis 100%
• Budesonide Foam 100%
• Endoscopic Remission 100%
• Rectal Foam 100%
• Confidence Interval 75%
• Mucosal Healing 75%
• 2-year Follow-up 50%
• Disease Duration 50%
• Hazard Ratio 25%
• Relapse-free Survival 25%
• Survival Time 25%
• Mayo Endoscopic Subscore 25%
• Phase III Clinical Trial 25%
• Maintenance of Remission 25%
• Proctosigmoiditis 25%
• Topical Preparation 25%
• Relapse Predictors 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Budesonide 100%
• Remission 100%
• Ulcerative Colitis 100%
• Disease Duration 22%
• Clinical Trial 11%
• Survival Time 11%
• Recurrence Free Survival 11%

Medicine and Dentistry

• Budesonide 100%
• Patient with Ulcerative Colitis 100%
• Ulcerative Colitis 50%
• Disease Duration 33%
• Hazard Ratio 16%
• Clinical Trial 16%
• Survival Time 16%
• Recurrence Free Survival 16%